Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), for which there are unmet needs surrounding its management. Four posters presented at international congresses in 2019 and 2020 investigated the management of SHPT, including the efficacy and safety of current and future treatments.
